Literature DB >> 19767779

Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin.

M Sakai, T Ikezoe, K Bandobashi, K Togitani, A Yokoyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19767779     DOI： 10.1038/bmt.2009.242

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  Acute kidney injury in HCT: an update.

Authors:  J A Lopes; S Jorge; M Neves
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

2.  Heterogeneous response to recombinant thrombomodulin by grade of sinusoidal obstructive syndrome after pediatric stem cell transplantation.

Authors:  J Inagaki; K Kurauchi; R Fukano; M Noguchi; J Okamura
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

3.  Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.

Authors:  Hiroyuki Matsui; Yasuyuki Arai; Hiroharu Imoto; Takaya Mitsuyoshi; Naoki Tamura; Tadakazu Kondo; Junya Kanda; Takayuki Ishikawa; Kazunori Imada; Yasunori Ueda; Yusuke Toda; Naoyuki Anzai; Kazuhiro Yago; Masaharu Nohgawa; Akihito Yonezawa; Hiroko Tsunemine; Mitsuru Itoh; Kazuyo Yamamoto; Masaaki Tsuji; Toshinori Moriguchi; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2020-07-14

4.  Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis.

Authors:  T Ikezoe; J Yang; C Nishioka; K Umezawa; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

Review 5.  New insights into postrenal transplant hemolytic uremic syndrome.

Authors:  Julien Zuber; Moglie Le Quintrec; Rebecca Sberro-Soussan; Chantal Loirat; Véronique Frémeaux-Bacchi; Christophe Legendre
Journal:  Nat Rev Nephrol       Date:  2010-11-23       Impact factor: 28.314

6.  Successful treatment of sepsis-induced disseminated intravascular coagulation in a patient with idiopathic thrombocytopenic purpura using recombinant human soluble thrombomodulin.

Authors:  Tomohiro Koga; Daisuke Inoue; Akitomo Okada; Toshiyuki Aramaki; Satoshi Yamasaki; Munetoshi Nakashima; Atsushi Kawakami; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2011-01-15       Impact factor: 2.631

Review 7.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

8.  Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen.

Authors:  T Ikezoe; J Yang; C Nishioka; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

9.  The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model.

Authors:  T Ikezoe; J Yang; C Nishioka; B Pan; K Xu; M Furihata; K Nakamura; H Yurimoto; Y Sakai; G Honda; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2016-07-18       Impact factor: 5.483

10.  Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation.

Authors:  Takayuki Ikezoe
Journal:  J Intensive Care       Date:  2015-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.